期刊文献+

阿昔洛韦脂质体的制备及其体外抗乙肝病毒的研究

Study on preparation of acydovir liposomes and its role in inhibiting hepatitics B in vitro
下载PDF
导出
摘要 目的制备阿昔洛韦脂质体并进行体外抗乙肝病毒作用研究。方法以反相蒸发法制备阿昔洛韦脂质体,同时考察其包封率的影响因素。以HPLC测定阿昔洛韦含量,透射电镜观察其形态,激光散射法测定其粒径大小,HepG2 2.2.15细胞模型检测阿昔洛韦脂质体对乙肝病毒HBs Ag和HBe Ag的抑制率。结果反相蒸发法中4℃时的包封率高于37℃时的包封率; 在本实验的PBS缓冲液离子强度范围内,随着离子强度升高,阿昔洛韦脂质体的包封率降低。脂质体中阿昔洛韦质量浓度为10.0,20.0,40.0,80.0 mg·L-1时对HBs Ag和HBe Ag的抑制率分别达到(7.5±1.2)%,(18.2±2.1)%,(52.6±2.7)%,(60.3±1.9)%和(8.3±0.8)%,(40.5±3.2)%,(47.4±1.2)%,(50.4±0.6)%。结论反相蒸发法可以制备阿昔洛韦脂质体;阿昔洛韦脂质体时HBs Ag和HBeAg有较好的抑制作用且明显优于游离阿昔洛韦。 OBJECTIVE To prepare acyclovir hposomes and study its ability to inhibit hepatitis B virus HBs Ag and HBe Ag. METHODS Acyclovir liposomes were prepared by reverse phase evaporation. Acyclovir was determined by HPLC and its partical size was determined by laser light scattering instrument. Transmission electron microscopy (TEM) was used to examine the morphology of liposomes. Its ability to inhibit hepatitis B virus HBs Ag and HBe Ag in vitro was studied by a HBV-transfectted cell line ( HepC2 2.2.15). RESULTS The encapsulation efficiency of liposomes prepared at 4℃was higher than that at 37 ℃. With the increase of PBS buffer ion strength, the encapsulation efficiency of liposomes decreased. The acyclovir concentrations of liposomes that inhibited HBs Ag in vitro by (7.5± 1.2) %, ( 18.2±2.1)% ,(52.6±2.7)%,(60.5±1.9)% and HBe Ag in vitro by (8.3±0.8)% ,(40.5±3.2)% ,(47.4±1.2)% ,(50.4±0.6)% were 10.0,20.0,40.0,80.0mg·L^-1. CONCLUSION Acyclovir liposomes are prepared by reverse phase evaporation, whose ability to inhibit hepatitis B virus HBs Ag and HBe Ag in vitro is better than acyclovir.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2005年第18期1396-1398,共3页 Chinese Pharmaceutical Journal
关键词 阿昔洛韦 脂质体 包封率 抗乙肝病毒 acyclovir liposomes encapsulation efficiency anti-HBV
  • 相关文献

参考文献9

  • 1蔡钦生,冯美卿,黄海,周.抗病毒前体药物的研究进展[J].中国新药杂志,2002,11(11):838-842. 被引量:7
  • 2Jones BM, Ma ES, Peiris JS, et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids[J]. Clin Exp Immunol,2004,125(3) :467.
  • 3Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome [J]. Proc Natl Acad Sci USA,2004,101(5): 1356.
  • 4Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons[ J]. Lancet ,2003,362(9380) :293.
  • 5Singleton WS, Gray MS, Brown ML, et al. Chromatogrphically homogeneous lecithin from egg phospholipids[J]. J Am Oil Chem Soc, 1965,42(1) :53.
  • 6Elorza B, Elorza MA, Sainz MC, et al. Comparison of particle size and encapsulation parameters of three liposommal preparations[ J]. J Microencapsulation, 1993,10( 2 ) :237.
  • 7Szoka FJ, Papahadjopoulous D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation[ J]. Proc Natl Acad Sci USA, 1978,75(9) :4194.
  • 8Norley SG, Huang L, Rouse BT. Targeting of drug loaded immunoliposomes to herpes aimplex virus infected corneal cells: an effective means of inhibiting virus replication in vitro [ J ]. J Immanol, 1986,136(2) :681.
  • 9Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery corneal penetration and absorption[ J]. J Controlled Release ,2000,63(1-2): 135.

二级参考文献29

  • 1Graeme M. The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy[J]. Drugs, 2001,61(1):19-26.
  • 2De Clercq E. Antiviral drugs: current state of the art [J].J Clin Virol ,2001,22(1) :73-89.
  • 3Karen M, Caroline MP. Oseltamivir: a review of its use in influenza[J].Drugs ,2001,61(2) :263-283.
  • 4Mckimm-Breschkin JL. Neuraminidase inhibitors for the treatment and prevention of influenza[J]. Expert Opin Pharmacother ,2002,3(2):103-112.
  • 5Martin K, René T. New, azide-free transformation of epoxides into 1,2-diamino compounds: synthesis of the anti-influenza neuraminidase inhibitor oseltamivir phosphate(Tamiflu)[J].J Org Chem,2001,66:2044-2051.
  • 6Choi WS, Im GJ, Kim TK, et al. Pharmacokinetic studies of 2-amino-9-(3-acetoxymethyl-4-isopropoxycarbonyb oxybut-1-yl)purine,an oral prodrug for the antiviral agent penciclovir[J].Drug Metab Dispos, 2001,29(7):945-949.
  • 7Tak RV, Pal D, Gao HE, et al. Transport of acylclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line[J].J Pharm Sci ,2001,90(10): 1505-1515.
  • 8Curran M, Noble S. Valganciclovir[J].Drugs, 2001,61(8):1145-1150.
  • 9Fiume L, Di Stefano G, Busi C, et al. Liver targeting of antiviral nucleoside analogues through the asialogly coprotein recepter[J].J Viral Hepat ,1997,4(6):363-370.
  • 10Bijsterbosch MK, van de Bilt H, van Berkel TJ, et al. Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles[J ].Biochem Pharmacol, 1996,52 (1):113-121.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部